We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Celgene has announced that the US Food and Drug Administration (FDA) has approved Revlimid (lenalidomide) in combination with rituximab (R2) for patients with ...
New trial results have been published showing that a combination of Celgene's Revlimid and Roche's rituximab (R2) significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placeb